Everything below concerns bioavailability. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-21. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
For the first time I no longer have to circumvent questions, I can at long last look everybody in the face. It is really a disgrace that we in South Africa have tolerated putting the Blacks and Coloured in a place, perhaps the worst place imaginable in our rugby grounds. We are now closing a book and entering a new era. South Africa will never be the same again. You know we must make changes towards a multi-racial deal not to placate or pander to overseas opinion but because it is the right and just thing. However, some, such as Chris Laidlaw, later a Labour MP in New Zealand, had had enough, and believed that rugby's failure to engage with the issue properly was harming the sport:
Vertical Agitation involves focusing on one part of a problem at a time, while holding oneself accountable for solving the problem – all the way to the highest level of government, business and society (such as advocating strongly for something: eco-friendly lightbulbs). This allows each individual in society to make vital "trivial" (read: small) changes, without being intimidated by the work needed to be done as a whole. Mackinnon added: a piecemeal approach also keeps individuals from becoming too 'holier than thou' (harassing friends and family about every possible improvement), where widespread practice of Vertical Agitation would lead to much improvement.
Down welling light intensity allows the bobtail squid to hide from predators by mimicking moonlight and starlight intensity as it hunts for prey at night. There is also development of blue crab defense, which utilizes sensory organs for detecting chemical changes in the water to alert them of predators. When alerted blue crabs will hide as a defensive strategy. The urine from predators acts as a selective pressure so that blue crabs which are more sensitive to chemical change are likely to survive. Those that survive increase the likelihood that offspring develop the same sensory organs for detection. However, there is a distinctive difference between development of the sensory organs, ability to process or accumulate toxins or bacteria compared to leaned or habit developing defensive strategy.
Sources: en.wikipedia.org
In 1984, the state passed legislation to allow the BPRC to lease space for such an eatery. The City Planning Commission also approved the structure the following year. However, the proposed café was met with opposition from the public, as it would obscure the library's rear facade. Several park advocates who opposed it argued that the proposed eatery would turn over part of a public park to a private entity. LeRoy withdrew from the project in 1986 due to this opposition, saying that he feared that the constant reviews of the plan would bring the proposed structure to "mediocrity". The renovation was approved by the City Art Commission in January 1987, though the restaurant plan had not yet been approved. Following LeRoy's withdrawal from the proposed Bryant Park café, the BPRC created a new plan with multiple smaller restaurant spaces. The spaces would be composed of two smaller pavilions, each 20 feet (6.1 m) tall with an area of 5,250 square feet (488 m2), flanking the Bryant memorial next to the library. In September 1987, the plans went to another vote before the City Art Commission, with the New York City Landmarks Preservation Commission taking an advisory role. The redesigned restaurant spaces were also approved by the City Art Commission that December, though the New York City Landmarks Preservation Commission registered no official position on the matter. A concessionaire for one of the spaces was found in 1988, and the same year, the city turned over duties of Bryant Park's land to BPRC. Subsequently, the park redesign was drafted by Hanna/Olin Ltd.
Kennedy (1919–2011), American biochemist at the Harvard Medical School known for work on lipid metabolism and membrane function. Dorothee Kern (born 1966), Biochemist at Brandeis University known for work on the motion of proteins using genomic data.
=== Foe === A foe is a unit of energy equal to 1044 joules (≈9.478×1040 BTU) that was invented by physicist Gerry Brown of Stony Brook University. To measure the staggeringly immense amount of energy produced by a supernova, specialists occasionally use the "foe", an acronym derived from the phrase [ten to the power of] fifty-one ergs, or 1051 ergs. This unit of measure is convenient because a supernova typically releases about one foe of observable energy in a very short period of time (which can be measured in seconds).
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.